An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Prior treatment

• Has participated in another investigational device or drug study or received an investigational device or drug \<1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
• Since completion of a previous study of aficamten has:Developed new-onset paroxysmal or permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g., direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) \<30 days prior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) \<100 bpm and/or rhythm is stable \>30 days.
• Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).
• History of appropriate implantable cardioverter defibrillator (ICD) shock within 30 days prior to screening.
• Has received treatment with mavacamten.

Lab values

• Had a confirmed LVEF \<40% with an associated dose interruption during participation in a prior study with aficamten.

• Completion of a Cytokinetics trial investigating CK-3773274
• LVEF ≥55% at the Screening Visit